← Leaderboards
Demonta Coleman
Texas A&M University
$117,343
Attributed
$117,343
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39.9K · FY2023–25$50K$37.5K$25K$12.5K$0
'23
'24
'25
Funding mix
By agency
NIH$117,343 · 1
By mechanism
F31$117,343 · 1
Top collaborators
No co-investigators on record.
Most similar at Texas A&M University
Same institution · by research overlap
- Wenshe Ray Liu$8,121,141
- Stephen H Safe$17,757,115
- Shiqing Xu$811,129
- Tadhg P. Begley$10,482,131
- Thomas R Ioerger$250,000
Others in their field
Other Rising Stars on “Antineoplastic Agents”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Syed Mukhtar Ahmed · Greenstone Biosciences, Inc.$2,741,939
- Choi-Fong Cho · Brigham And Women'S Hospital$2,666,597
- Nadine Norton · Mayo Clinic Jacksonville$2,431,858
- Edwin Manuel · Beckman Research Institute/City Of Hope$2,258,119
- Faith H Barnett · Resolute Science, Inc.$2,123,874
Research focus
Antineoplastic AgentsBacteriophagesBindingBiotinylationCancer Cell LineCancer TherapyCancer TypeCd44 GeneCell Growth RegulationCell LineCellsClinical TrialsConsensusConsensus SequenceCyclic PeptidesCyclizationDependenceDesignDetectionDimensionsDockingDrug DesignDrug DevelopmentAffinity
Grant awards (3)
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route$39,917
F31 · FY2025 · CA · contact PI
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route$39,353
F31 · FY2024 · CA · contact PI
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route$38,073
F31 · FY2023 · CA · contact PI